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Influenza hemagglutinin (HA) is the primary target of the humoral
response during infection/vaccination. Current influenza vaccines
typically fail to elicit/boost broadly neutralizing antibodies (bnAbs),
thereby limiting their efficacy. Although several bnAbs bind to the
conserved stem domain of HA, focusing the immune response to
this conserved stem in the presence of the immunodominant,
variable head domain of HA is challenging. We report the design
of a thermotolerant, disulfide-free, and trimeric HA stem-fragment
immunogen which mimics the native, prefusion conformation of HA
and binds conformation specific bnAbs with high affinity. The im-
munogen elicited bnAbs that neutralized highly divergent group 1
(H1 and H5 subtypes) and 2 (H3 subtype) influenza virus strains in
vitro. Stem immunogens designed from unmatched, highly drifted
influenza strains conferred robust protection against a lethal heter-
ologous A/Puerto Rico/8/34 virus challenge in vivo. Soluble, bac-
terial expression of such designed immunogens allows for rapid
scale-up during pandemic outbreaks.
hemagglutinin stalk | stabilization | cross-protection |
pandemic preparedness | Escherichia coli
Seasonal influenza outbreaks across the globe cause an esti-mated 250,000–500,000 deaths annually (1). Current in-
fluenza vaccines need to be updated every few years because of
antigenic drift (2). Despite intensive monitoring, strain mismatch
between vaccine formulation and influenza viruses circulating
within the population has occurred in the past (2). Public health is
further compromised when an unpredictable mixing event among
influenza virus genomes leads to antigenic shift facilitating a po-
tential pandemic outbreak. These concerns have expedited efforts
toward developing a universal influenza vaccine.
Neutralizing antibodies (nAbs) against hemagglutinin (HA)
are the primary correlate for protection in humans and hence
HA is an attractive target for vaccine development (3). The
precursor polypeptide, HA0, is assembled into a trimer along the
secretory pathway and transported to the cell surface. Cleavage
of HA0 generates the disulfide-linked HA1 and HA2 subunits.
Mature HA has a globular head domain which mediates receptor
binding and is primarily composed of the HA1 subunit, whereas
the stem domain predominantly comprises the HA2 subunit. The
HA stem is trapped in a metastable state and undergoes an ex-
tensive low-pH-induced conformational rearrangement in the
host-cell endosomes to adopt the virus–host membrane fusion-
competent state (4, 5).
The antigenic sites on the globular head of HA are subjected
to heightened immune pressure resulting in escape variants,
thereby limiting the breadth of head-directed nAbs (6). How-
ever, extensive efforts have resulted in the isolation of mono-
clonal antibodies (mAbs) that bind within the globular head and
inhibit receptor attachment, which neutralize drifted variants of
an HA subtype or heterosubtypic HA (7–16). The HA stem is
targeted by several broadly neutralizing antibodies (bnAbs) with
neutralizing activity against diverse influenza A virus subtypes
(17). The epitopes of these bnAbs in the HA stem are more
conserved across different influenza HA subtypes compared with
the antigenic sites in the HA globular head (18).
During a primary infection, the immunodominant globular
head domain suppresses the response toward the conserved
stem. Several efforts have been made to circumvent this prob-
lem. Repeated immunizations with full-length, chimeric HAs
(cHAs) in a protracted vaccination regimen have been shown to
boost stem-directed responses in mice (19). Alternatively, full-
length HA presented on nanoparticles (np) has been shown to
elicit stem-directed nAbs (20). Attempts have also been made to
steer the immune response toward the conserved HA stem by
hyperglycosylating the head domain (21). Although the afore-
mentioned strategies need to be further evaluated and provide
novel alternatives, detrimental interference from the highly
variable immunodominant head domain in eliciting a broad
functional response cannot be completely evaded. A “headless”
stem domain immunogen offers an attractive solution. However,
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early attempts at expressing the HA2 subunit independently in
a native, prefusion conformation were unsuccessful. In the absence
of the head domain, the HA2 subunit expressed in Escherichia coli
spontaneously adopted the low-pH conformation (22) in which the
functional epitopes of stem-directed bnAbs are disrupted. More
recently, the entire HA stem region has been expressed in a pre-
fusion, native-like conformation in both prokaryotic and eukaryotic
systems adopting multiple strategies (23–26).
Design of independently folding HA stem fragments which
adopt the prefusion HA conformation presents another ap-
proach to elicit bnAbs against influenza (27, 28). The A helix of
the HA2 subunit contributes substantial contact surface to the
epitope of stem-directed bnAbs such as CR6261, F10, and oth-
ers. Although multivalent display of A helix on the flock house
virus as a virus-like particle platform elicited cross-reactive anti-
bodies, it conferred only minimal protection (20%) against virus
challenge in mice (29).
We report the design and characterization of engineered head-
less HA stem immunogens based on the influenza A/Puerto Rico/
8/34 (H1N1) subtype. H1HA10-Foldon, a trimeric derivative of our
parent construct (H1HA10), bound conformation-sensitive, stem-
directed bnAbs such as CR6261 (30), F10 (31), and FI6v3 (32) with
a high-affinity [equilibrium dissociation constant (KD) of 10–50
nM]. The designed immunogens elicited broadly cross-reactive
antiviral antibodies which neutralized highly drifted influenza vi-
rus strains belonging to both group 1 (H1 and H5 subtypes) and
2 (H3 subtype) in vitro. Significantly, stem immunogens designed
from unmatched, highly drifted influenza strains conferred pro-
tection against a lethal (2LD90) heterologous A/Puerto Rico/8/34
virus challenge in mice. Our immunogens confer robust subtype-
specific and modest heterosubtypic protection in vivo. In contrast
to previous stem domain immunogens (23–25), the designed
immunogens were purified from the soluble fraction in E. coli. The
HA stem-fragment immunogens do not aggregate even at high
concentrations and are cysteine-free, which eliminates the com-
plications arising from incorrect disulfide-linked, misfolded con-
formations. The aforementioned properties of the HA stem-
fragment immunogens make it amenable for scalability at short
notice which is vital during pandemic outbreaks.
Results
Immunogen Design. Antigenic differences between the HA sur-
face glycoprotein of various influenza A viruses provide the basis
for classification into 18 subtypes (H1–H18) (33). Wide diversity
and rapid antigenic variation of HA remains the principal chal-
lenge to the development of potent vaccines. Targeting con-
served regions of HA offers a promising strategy to combat viral
evolution and escape. We analyzed a large dataset (4,241 se-
quences for H1N1 and 182 sequences for H5N1) of group 1
influenza virus sequences to identify conserved targets on HA.
Consistent with previous results (18), the HA stem is more
conserved as opposed to the highly variable, globular head do-
main. The residue conservation across all full-length, human
isolates of H1 HA (Fig. 1A) and group 1 HA (Fig. 1B) was
mapped onto the crystal structure of H1N1 A/Puerto Rico/8/34
HA [Protein Data Bank (PDB) ID code 1RU7] (34). The HA
stem comprising the epitope of bnAbs is therefore a plausible
target for developing a broadly protective vaccine (35).
Mimicking the epitope of these stem-directed bnAbs in a na-
tive, prefusion conformation in a headless stem immunogen is
challenging because of the metastable conformation of HA. The
HA2 subunit, when expressed independently, adopts the low-pH
conformation spontaneously (22). Extensive rearrangement at
Fig. 1. The HA stem is conserved. (A) Residue con-
servation among H1 HA isolates mapped onto the
surface representation of H1N1 A/Puerto Rico/8/34
HA trimer (PDB ID code 1RU7) (34). All residues in
a monomer are colored according to the quality
score (Q score) at that position obtained from
a multiple-sequence alignment of H1N1 HA sequen-
ces using ClustalX (56). The head domain is highly
variable as opposed to the conserved stem domain.
The stem-directed bnAb CR6261 epitope (box) is
highly conserved. Rest of HA (gray). (B) Residue
conservation across group 1 HA (H1N1 and H5N1
subtype HA sequences were analyzed) mapped onto
a H1N1 A/Puerto Rico/8/34 HA trimer (PDB ID code
1RU7). Despite the increased variation in HA across
group 1 influenza A subtypes as opposed to within
a subtype (H1), the epitope of the stem-directed
bnAb CR6261 (box) is well conserved. Rest of HA
(gray). (C) Cartoon representation of H1HA10. One
monomer is colored according to the conservation
scheme shown in A. In a second monomer, linker
connectivity is shown (dashed black line). The first
fragment 181–411 (pink) was connected to 2901–3231
(purple) by a three-residue GSA linker. The HA1
(purple) and HA2 fragments (gray) were connected
by a six-residue linker (GSAGSA). The HA2 fragment
(412–1132) included in H1HA10 incorporates elements
of A helix and LAH of the HA2 subunit. Rest of HA
(light gray). (D) Fragments of the HA stem defined by
stable breakpoints were included in our preliminary
construct H1HA10. The fragments were connected by flexible, soluble linkers. Derivatives of H1HA10 with C-terminal trimerization motifs, IZ or Foldon, were
made (41, 42). (E) Mutations introduced in H1HA10 are shown in a monomer model. The HA1 fragments are colored light blue, whereas the HA2 fragment is in
light green. Mutations were introduced to mask the hydrophobic patch [I2981T, V3011T, I3031N in the HA1 fragments (red); and V662T, F1102A in the HA2
fragment (pink)]. An additional mutation [C3061S (purple)] was made to prevent intermolecular disulfide bond formation. Mutations were also introduced to
destabilize the low-pH conformation of HA [F632D and L732D (orange)]. Residues S542 and N822 present in the A/Puerto Rico/8/34 HA crystal structure (PDB ID
code 1RU7) were mutated to the most commonly occurring residues T542 and K582 (sky blue) in a multiple-sequence alignment of all available full-length
H1N1 A/Puerto Rico/8/34 HA sequences. The figures were rendered using PyMOL.
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low pH displaces the A helix by over 100 Å (5), disrupting the
conformation-specific epitope of these bnAbs.
To enhance the immune response to the epitope of the HA
stem-directed bnAbs like CR6261, F10, and FI6v3 (30–32), we
adopted a protein-minimization approach to refine the previously
reported HA stem immunogens, H1HA6 and H1HA0HA6. These
HA stem immunogens consisted of the entire stem region of HA
and were 258 (H1HA6) and 243 (H1HA0HA6) residues in length
(24). Smaller, headless HA stem immunogens that contained the
above epitope were designed from the influenza A (H1N1) A/
Puerto Rico/8/34 subtype. We analyzed the interaction network of
residues in the antibody footprint of these bnAbs with the rest of
HA using the in-house software PREDBURASA as described
previously (36). Briefly, the accessible surface area (ASA) of every
residue in HA was calculated in the absence and presence of at
least three-residue-long stretches of the CR6261 antibody foot-
print (321–361, 2921–2941, 182–212, 362–562), covering ∼95% of
the CR6261 epitope. Residues belonging to either HA1 or HA2
subunits are distinguished by subscripts 1 and 2, respectively. All
residues of HA, which had a total side-chain ASA difference of ≥5
Å2 in the aforementioned calculations, were identified as inter-
acting “network” residues. We repeated the PREDBURASA
calculations now including the network residues to identify HA
stem fragments defined by stable breakpoints with optimal termini
distances, having minimalistic interactions with the rest of HA.
Residue fragments 181–411, 2901–3231, and 412–1132 were in-
cluded in H1HA10 (Fig. 1 C and D). H1HA10 includes ∼80% of
the CR6261 antibody footprint. H1HA10 is 139 residues in length
and is therefore ∼46% smaller than the full-length HA stem im-
munogen described previously (24). The newly generated exposed
hydrophobic patches in H1HA10 due to interactions lost with the
rest of HA were mutated using the software ROSETTA DESIGN
(Version 3.0) (37) to minimize potential protein aggregation. A
similar approach has been previously used by us to design stable
influenza and HIV immunogens and inhibitors (24, 38, 39). The
following mutations were incorporated to mask the hydrophobic
patch: I2981T, V3011T, I3031N, V662T, and F1102A (Fig. 1E; Fig.
S1). Cys2811 and Cys3061 form an intramolecular disulfide bond
in full-length HA. Because Cys2811 was not incorporated in our
design, we mutated Cys3061 to Ser to prevent incorrect, in-
termolecular disulfide bond formation. Low-pH conformation
destabilizing mutations F632D and L732D, which were previously
characterized (24) by us, were also incorporated in the design.
Residues S542 and N822 present in the A/Puerto Rico/8/34 HA
crystal structure (PDB ID code 1RU7) were replaced in H1HA10
with the most commonly occurring residue (T542 and K822) at
that position among all of the available H1N1 A/Puerto Rico/8/34
sequences deposited with the National Center for Biotechnology
Information (NCBI) Influenza Virus Database (www.ncbi.nlm.nih.
gov/genomes/FLU/FLU.html). None of the introduced mutations
were in the epitopes of the previously reported stem-directed bnAbs
CR6261, F10, or FI6v3. These independent HA fragments were
connected by flexible, soluble linkers of appropriate length as de-
scribed previously (40) (Fig. 1D; Fig. S1). Also to promote the
formation of a trimer, we made derivatives of H1HA10 with C-
terminal trimerization motifs connected by flexible linkers. The
parallel, coiled-coil trimerization motif isoleucine zipper (IZ) (41)
was used in H1HA10-IZ. H1HA10-Foldon had the globular, β-rich
trimerization motif “Foldon” (42) (Fig. 1D).
To assess the ability of our stem immunogens to confer cross-
protection, constructs similar to H1HA10-Foldon were designed
from unmatched, highly drifted influenza strains (Table S1) and
tested against heterologous A/Puerto Rico/8/34 virus challenge
in mice. The alternative approach of immunizing with our
headless stem constructs designed from H1N1 A/Puerto Rico/8/
34 and carrying out heterologous virus challenge could not
be tested because of the unavailability of appropriate mouse-
adapted virus strains other than H1N1 A/Puerto Rico/8/34.
Constructs from other strains [H1N1 A/New Caledonia/20/99
(NCH1HA10-Foldon), H1N1 A/California/04/2009 (pH1HA10-
Foldon), and H5N1 A/Viet Nam/1203/2004 (H5HA10-Foldon)]
were designed using a facile strategy. A simplistic, pair-wise
sequence alignment, which can guide immunogen design, empha-
sizes the utility of our design (Fig. S2). The hydrophobic residues
mutated in H1HA10 to mask the newly generated hydrophobic
patches are identical/similar within a subtype, therefore, analogous
mutations can be included in H1HA10-like designs from other
strains. Wide applicability of the mutations destabilizing the low-pH
conformation of HA has been previously discussed (24). The
sequences of all of the designed constructs are listed in Fig. S1.
Protein Purification and Biophysical Characterization of HA Stem
Immunogens. Protein solubility is a coarse indicator of proper
folding and remains a crucial problem in heterologous expres-
sion systems (43). HA fragments expressed previously in E. coli
formed inclusion body aggregates and required refolding (24,
44). In contrast, all our designed immunogens expressed in
E. coli BL21(DE3) cells were purified from the soluble fraction
of the cell culture lysate (Fig. S3), suggesting proper folding and
validating our rational design. The protein yields were about 10–
15 mg/L culture using unoptimized shake flask cultures and were
purified using a single, affinity purification step.
Circular dichroism (CD) spectra indicated that all of the
proteins were folded and predominantly α-helical as expected.
The trimerization motifs assist in the folding of H1HA10.
H1HA10-IZ and H1HA10-Foldon are more helical than the
parent construct, H1HA10, as observed from the double minima
at 208 and 222 nm (Fig. 2A). The thermal stability of H1HA10-
Foldon was monitored using CD. H1HA10-Foldon showed a
reversible and cooperative unfolding thermal melt profile with
an apparent transition midpoint (Tm) of ∼323 K (50 °C) at
a protein concentration (in monomer units) of ∼15 μM. Because
the folded protein is a trimer and the unfolded protein is likely to
be a monomer, the Tm is expected to be concentration de-
pendent (41). Consecutive scans recorded after cooling the
sample back to 15 °C overlapped well with each other (Fig. S4A).
In contrast, the full-length H1N1 A/Puerto Rico/8/34 rHA
showed a broad transition without clear baselines and it was
therefore not possible to estimate a Tm. The rescan showed no
transition, indicating that thermal denaturation for rHA is irre-
versible (Fig. S4B). Intrinsic tryptophan fluorescence measure-
ments also affirmed a folded, native structure for H1HA10 and
its derivatives. All proteins showed a significant red-shift in the
emission maxima upon denaturation with guanidine hydrochlo-
ride (GdnCl) (Fig. S5).
Furthermore, the 1D 1H-NMR spectrum of H1HA10-foldon
exhibits solution properties characteristic of a well-folded protein
molecule. The presence of resolved resonance lines that appear in
the downfield (9–11 ppm) and the upfield (0.5 to –1 ppm) regions
of the spectrum are clear indicators that the molecule adopts
a stable tertiary structure (Fig. 2B). The upfield-shifted signals are
those of methyl protons that are spatially proximal to aromatic rings
in the interior of the protein (hydrophobic core). The conforma-
tional stability of the folded state of H1HA10-Foldon was further
probed by hydrogen exchange studies. The slow exchange of the
amide protons in the downfield (9–11 ppm) region of 1D 1H-NMR
spectrum is suggestive of a well-packed molecule (Fig. S6).
H1HA10-Foldon Is a Homogenous Trimer in Solution and Resistant to
Proteolysis. The long central α-helices (LAHs) located in the HA
stem assemble together into a parallel, trimeric coiled-coil pro-
moting oligomerization. The oligomeric state of the designed
immunogens was probed by analytical gel-filtration chromatog-
raphy under native conditions. H1HA10 eluted predominantly as
a monomer and a minor trimeric peak. This was probably be-
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cause in the absence of the transmembrane (TM) domain of HA,
the trimer is not stable (45). It has previously been demonstrated
that trimerization motifs facilitate oligomerization in the absence
of the HA TM domain (46). Both IZ and Foldon trimerization
sequences aided in trimerization of H1HA10. H1HA10-IZ formed
a mixture of stable trimeric (∼65%) and monomeric (∼35%) con-
formers in solution which did not reequilibrate when partitioned.
H1HA10-Foldon eluted exclusively as a trimer in solution (Fig. 2C).
In contrast to previously designed immunogens H1HA6 and
H1HA0HA6, which contain the entire stem domain (24), none of
the proteins characterized in this study were aggregation prone.
Gel-filtration studies indicate that we have effectively resurfaced
exposed hydrophobic patches in our designed constructs.
Misfolded proteins having disordered sectors are subjected to
increased proteolysis. H1HA10 showed limited resistance to
proteolysis (trypsin digestion) compared with a control unfolded
protein [reduced and carboxamidated ribonuclease A (RCAM-
RNaseA)]. Proteolytic stability increased in the order H1HA10 <
H1HA10-IZ < H1HA10-Foldon. Proteolysis confirmed a compact,
folded conformation for H1HA10-Foldon (Fig. 2D).
Headless Stem Immunogens Bind Conformation-Specific bnAbs.
Stem-directed bnAbs like CR6261, F10, and FI6v3 bind the
native, neutral-pH conformation of HA with high affinity (30–
32). Epitopes of these bnAbs are disrupted in the low-pH, fusion-
competent conformation of HA. Therefore, the ability of
stem-derived immunogens to bind these bnAbs offers a robust
validation of their conformation.
Binding of the designed headless stem immunogens to the
bnAbs was determined by surface plasmon resonance (SPR).
H1HA10 bound IgG CR6261 with submicromolar affinity (315.4 ±
14.5 nM) (Table 1; Fig. S7). As previously mentioned, H1HA10
has ∼80% of the antibody-footprint. H1HA10 although folded, is
monomeric and not particularly compact as implied from pro-
teolysis. These factors may contribute to the high koff, which would
decrease the binding affinity (Table 1). Derivatives of H1HA10,
which had improved biophysical and biochemical properties had
considerably tighter binding to CR6261. H1HA10-IZ had a KD of
73.9 ± 2.3 nM. The conformational heterogeneity of H1HA10-IZ
in solution may possibly lead to the observed biphasic binding
to CR6261 at higher concentrations (trace 1 in Fig. S7B) as ob-
served previously with the HA stem immunogen H1HA6 (24).
H1HA10-Foldon, which assembles into a homogenous trimer
in solution, bound CR6261 with the highest affinity among the
designed stem immunogens (52.4 ± 1.8nM). Although H1HA10-
Foldon binds CR6261 with about a sixfold weaker affinity than
full-length A/Puerto Rico/8/34 recombinant HA (rHA) (8.9 ± 0.3
nM) (Table 1), it is a significant improvement over the previously
reported stem immunogen H1HA6 (∼260 nM) (24), which com-
prised the entire HA stem with the complete CR6261 epitope.
Binding of H1HA10-Foldon to the single-chain variable fragment
(scFv) derivatives of other stem-directed bnAbs (F10 and FI6v3)
was also determined to confirm the native, prefusion HA-like
conformation of H1HA10-Foldon. The slower off-rates for both
H1HA10-Foldon and A/Puerto Rico/8/34 rHA result in a higher
affinity to F10-scFV in comparison with IgG CR6261 (Table 1; Fig.
S8 A and C). The KD of H1HA10-Foldon binding to F10-scFv was
9.8 ± 2.1nM, about threefold weaker than full-length A/Puerto
Rico/8/34 rHA (2.9 ± 0.9 nM). H1HA10-Foldon also bound FI6v3
(the pan-influenza binding antibody) with a low KD of 12.1 ± 3.4
nM (Table 1; Fig. S8 B and D).
Thermal tolerance, a pharmaceutically relevant parameter,
was assessed by determining the KD of H1HA10-Foldon binding
to CR6261 after prolonged heat stress. H1HA10-Foldon bound
CR6261 with a KD of 71.6 ± 0.5 nM even after incubating the
protein at 80 °C for 1 h (see the second footnote to Table 1).
The specificity of H1HA10-Foldon binding to IgG CR6261
was also confirmed in a pull-down assay. Protein G beads (GE
HealthCare) specific for human IgG CR6261 were used to pull
down the antibody–antigen complex (Fig. S9).
HA Stem Immunogens Elicit Broadly Cross-Reactive, Neutralizing
Antibodies. During natural infection, the immunodominant head
domain steers the immune response away from the conserved
stem (47). This is probably the reason why there are low/un-
detectable cross-reactive antibodies in the anti-A/Puerto Rico/8/
34 convalescent sera. In contrast, high titers of cross-reactive
antibodies are elicited by our stem domain immunogens (Fig. 3;
Fig. 2. Biophysical and biochemical characteriza-
tion of headless HA stem immunogens. (A) Second-
ary structure of the designed immunogens were
monitored by CD spectroscopy. H1HA10 was folded
and predominantly α-helical. The trimerization motifs,
IZ and Foldon, assist in the folding of H1HA10. The
double minima at 208 and 222 nm indicate that
H1HA10-IZ and H1HA10-Foldon are more helical than
H1HA10. The samples were in PBS (pH 7.4). (B) One-
dimensional 1H NMR spectra of H1HA10-Foldon. The
chemical shift dispersion indicates the protein is well
folded. The upfield-shifted lines in the methyl group
region starting at 0.6 ppm are indicated by an arrow.
The chemical shift dispersion in the amide region is
highlighted by a bar. (C) Oligomeric state of the
designed immunogens was determined by analytical
gel-filtration chromatography under nondenaturing
conditions on a Superdex-200 column in PBS (pH 7.4) at
room temperature. H1HA10 eluted predominantly as
a monomer, H1HA10-IZ as a mixture of trimer and
monomer, and H1HA10-Foldon as a homogenous tri-
mer in solution. The column was calibrated using a
broad range of molecular weight markers (×). Trimer
peaks of the HA stem immunogens are represented by
open circles (○) and the monomer peaks are repre-
sented by closed circles (●) (Inset). (D) Proteolysis of HA stem immunogens. Aliquots of the test proteins at the indicated time points (0, 15, 30, 45, and 60 min) were
quenched with 0.1% formic acid. The samples were analyzed by SDS/PAGE. Lanes: 1–5, RCAM-RNaseA; 6–10, H1HA10; 11–15, H1HA10-IZ; 16–20, H1HA10-Foldon, and
21, prestained broad rangemarker (Biorad). RCAM-RNaseAwas completely digested within 15min. Proteolytic resistance increased as follows: H1HA10 <H1HA10-IZ <
H1HA10-Foldon, confirming that H1HA10-Foldon adopts a compact, folded conformation.
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Table S2) confirming that the immunogens have adopted a native-
like, neutral-pH conformation. H1HA10-Foldon elicited the
highest cross-reactive antibody titers (in the range of 409,600
to 1,638,400) with group 1 HAs (Fig. 3 A–D). H1HA10-Foldon
bound the pan-influenza nAb FI6v3 with high affinity, which
prompted us to examine the ability of anti–H1HA10-Foldon sera
to bind group 2 HAs. Interestingly, H1HA10-Foldon elicited
moderate titers (25,600) of cross-reactive antibodies against
(group 2) H3 HAs (Fig. 3 E and F). However, additional design
optimization incorporating the sequence variation information
among the stem of all HA subtypes will be essential to formulate
an immunogen that can elicit a truly universal response.
Neutralization titers for the various antisera were measured
using a pseudotype neutralization assay (48). Current vaccination
strategies with whole inactivated viruses typically fail to elicit/
boost cross-reactive nAbs (49). Consistent with this, the anti-A/
Puerto Rico/8/34 convalescent sera showed low or undetectable
neutralization of drifted influenza strains. In contrast, sera from
mice immunized with the HA stem immunogens showed robust
neutralization of the highly divergent H1 A/New Caledonia/20/
1999 and H1 A/Brisbane/59/2007 influenza viruses. The sera
also showed measurable neutralization of the highly pathogenic
H1 A/South Carolina/1/1918 and avian H5 A/Viet Nam/1194/
2004 influenza viruses. Impressively, the sera also showed neu-
tralization activity against a group 2 virus (H3 A/Udorn/307/
1972) (Fig. 3G).
Antibodies elicited by the HA stem immunogens probably
mediate virus neutralization by inhibiting virus–host cell mem-
brane fusion as inferred from their ability to compete with the stem-
directed bnAb IgG-CR6261 for binding to H1N1 A/California/04/
2009 rHA (Fig. 3H). The sera elicited against H1HA10-Foldon
showed maximum competition with CR6261, in accordance with
the improved biophysical/biochemical properties of the immu-
nogen. The competition assay demonstrates the presence of
CR6261-like antibodies following immunization with headless
stem immunogens. As a control, the nAb MA2077 which binds at
the Sa antigenic site on H1N1 A/California/04/2009 HA (50)
failed to compete with CR6261.
The sera were not tested in a HA inhibition assay because the
stem-directed bnAbs mediate neutralization by inhibiting mem-
brane-fusion and not by blocking the virus from binding to
receptors on the host cells (51).
H1HA10-Foldon Completely Protects Against a Lethal Homologous
Virus Challenge. All of the headless constructs elicited a robust
immune response in mice with high serum antibody self-titers
(>1,638,400). Twenty-one days postsecondary immunization,
mice were challenged intranasally with a lethal dose (1LD90) of
homologous A/Puerto Rico/8/34 virus. The challenged mice
showed significant weight recovery by the end of the observation
period after initial weight loss (Fig. 4B). The monomeric immu-
nogen H1HA10 conferred 50% protection, whereas its compact,
trimeric derivative H1HA10-Foldon protected mice completely
from a lethal homologous virus challenge (Fig. 4A). Notably, im-
munization with H1HA10-Foldon gave improved protection in
comparison with a previously reported stem immunogen H1HA6
(24). The extent of weight loss was also slightly lower for mice
immunized with H1HA10-Foldon relative to H1HA6. Immuni-
zation with H1HA10-Foldon also provided significant protection
against a higher challenge dose (2LD90) of the virus (Fig. 5A).
HA Stem Immunogens Confer Robust Subtype-Specific Protection.
Immunogens designed from unmatched, highly drifted influenza
strains (Fig. S2) also elicited a robust immune response in mice
with high serum antibody self-titers (≥1,638,400). The ability of
stem immunogens to provide cross-protection was tested against
a heightened challenge dose (2LD90) of heterologous A/Puerto
Rico/8/34 virus in mice. All of the immunogens significantly
delayed viral infection (Fig. 5 A and C). NCH1HA10-Foldon
conferred robust protection (Fig. 5A), emphasizing the protective
ability of stem immunogens across decades of genetic drift. Im-
pressively, the stem fragment NCH1HA10-Foldon designed from
a drifted strain (H1N1 A/New Caledonia/20/1999) had greater
efficacy relative to the full-length stem domain H1HA6 (designed
from H1N1 A/Puerto Rico/8/34) against A/Puerto Rico/8/34 virus
challenge. H5HA10-Foldon, designed from an H5 subtype in-
fluenza strain (H5N1 A/Viet Nam/1203/2004) also provided
partial protection and the surviving mice showed significant weight
recovery (Fig. 5B). H1HA10-Foldon elicited significant titers of
cross-group HA-specific antibodies which neutralized an H3 virus
(Fig. 3 E–G). Hence, the protective ability of pH1HA10-Fol-
don against a group 2 H3N2 A/Hong Kong/68 virus challenge
(2LD90) was also tested. The immunogen delayed infection and
conferred weak protection (Fig. 5C). Surviving mice showed
significant weight recovery (Fig. 5D). Our designed headless
stem-fragment immunogens confer robust subtype-specific and
weak cross-group protection in vivo.
Discussion
We have successfully engineered stem-domain fragments of HA
to adopt the native, neutral-pH-like conformation in the absence
of the globular head. Our design can readily be extended to other
strains as discussed, emphasizing its wide applicability. The head-
less immunogens provide an efficient strategy to evade interference
Table 1. HA stem immunogens bind bnAbs with high affinity
Immunogen Ligand* kon, M
−1·s−1 koff, s
−1 KD, nM
H1HA10 CR6261-IgG 2.49 ± 0.08 × 104 7.85 ± 0.09 × 10−3 315.4 ± 14.5
H1HA10-IZ CR6261-IgG 6.55 ± 0.51 × 104 4.84 ± 0.11 × 10−3 73.9 ± 2.3
CR6261-IgG 3.72 ± 0.22 × 104 1.95 ± 0.19 × 10−3 52.4 ± 1.8†
H1HA10-Foldon F10-scFv 1.54 ± 0.14 × 105 1.50 ± 0.20 × 10−3 9.8 ± 2.1
FI6v3-scFv 1.69 ± 0.53 × 105 2.05 ± 0.12 × 10−3 12.1 ± 3.4
CR6261-IgG 2.89 ± 0.02 × 105 2.58 ± 0.08 × 10−3 8.9 ± 0.3
H1 A/Puerto Rico/8/34 rHA F10-scFv 4.15 ± 0.61 × 105 1.21 ± 0.21 × 10−3 2.9 ± 0.9
FI6v3-scFv 2.45 ± 0.06 × 105 2.16 ± 0.27 × 10−3 8.8 ± 1.1
Kinetic parameters for binding of conformation-specific bnAbs to HA stem immunogens and full-length rHA
by SPR.
*Five hundred RU of CR6261-IgG were immobilized on the surface of a CM5-chip. F10-scFv and FI6v3-scFv were
immobilized to a density of 750 RU.
†Binding of H1HA10-Foldon to CR6261 was monitored after heat stress. The protein was incubated at 40 °C, 60 °C,
and 80 °C for 1 h and the KD to CR6261 at 25 °C was determined. H1HA10-Foldon retained its ability to bind CR6261
even after heating at 80 °C. The KD after various heat stresses; 40 °C (55.7 ± 0.9 nM), 60 °C (61.4 ± 1.3 nM), and 80 °C
(71.6 ± 0.5 nM).
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from the highly variable immunodominant head domain in the
hope of broadening a vaccine response, which is validated by the
broad spectrum neutralization profile of the antibodies elicited by
our HA stem-fragment immunogens.
In a series of earlier studies, immunization with full-length
cHA with a globular head from heterologous influenza strains
(H9, H6, and H5, all belonging to group 1) and stem from H1N1
A/Puerto Rico/8/34 (group 1) was shown to protect against ho-
mologous and heterologous group 1 virus challenge. The animals
were immunologically naïve to the head domain of the challenge
virus (19). A prolonged immunization regimen was adopted in
the cHA study with a primary DNA vaccination followed by two
boosts with cHA recombinant protein administered both in-
tranasally and intramuscularly. More recently, intramuscular
immunizations (prime-boost) with different combinations of
cHA proteins with diverse heads and a A/Puerto Rico/8/34
stem, were shown to protect mice against A/Puerto Rico/8/34 and
pandemic H1N1 challenge. A precise comparison with the present
work is difficult because of the differences in challenge viruses and
doses used in the two studies (52). Although this is a promising
approach and immunizations with cHAs elicit stem-directed Abs,
the contribution of the head-directed immune response to protec-
tion is difficult to evaluate in these studies. Antibody responses to
the head domains used in the cHAs may also interfere or depress
titer of stem directed antibodies. We have circumvented this issue
altogether by designing stable headless stem immunogens. Our
study highlights the applicability of the reported HA stem-fragment
immunogens to elicit stem-directed nAbs in a curtailed prime-boost
immunization regimen.
Fig. 3. Headless HA stem immunogens elicit broadly cross-reactive, nAbs in mice. Breadth of the antibody response elicited by the designed immunogens was
determined by ELISA of the pooled antisera (n = 10 mice per group) against purified rHA proteins (A) H1N1 A/Puerto Rico/8/34, (B) H1N1 A/California/04/2009,
(C) H1N1 A/Brisbane/59/2007, (D) H5N1 A/Viet Nam/1194/2004, (E) H3N2 A/Aichi/2/68, and (F) H3N2 A/Brisbane/10/07. All of the stem immunogens elicited
higher cross-reactive antibody titers compared with mice immunized with A/Puerto Rico/8/34 virus. H1HA10-Foldon elicited the highest cross-reactive anti-
body titers. (G) Neutralization of heterologous influenza virus strains by the H1N1 A/Puerto Rico/8/34 sequence-derived HA stem-immunized mice sera. IC50
titer is the reciprocal of sera dilution at which half-maximal neutralization was observed. The neutralization strength is color coded from green (weak) to red
(strong). An IC50 value of zero indicates no detectable neutralization. The neutralization assay was performed against a panel of influenza HA strains: A/
Puerto Rico/8/34 [PR34 (H1)], A/New Caledonia/20/1999 [NC99 (H1)], A/Brisbane/59/2007 [Bris07 (H1)], A/South Carolina/1/1918 [SC1918 (H1)], A/Viet Nam/1194/
2004 [VN04 (H5)], and A/Udorn/307/1972 [Udorn72 (H3)]. (H) HA stem-immunized mice sera compete with the bnAb CR6261. Antisera from mice immunized
with the designed headless stem immunogens were tested for competition binding to H1N1 A/California/04/2009 rHA in the presence of 300 ng/mL CR6261
(24). H1HA10-Foldon antisera showed maximum competition with CR6261. Although all of the stem-immunized mice sera competed with CR6261, the control
head-specific mAb MA2077 (binds at the Sa antigenic site on HA) (50) did not compete with CR6261.
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In another study, repetitive arrays of full-length HA were
successfully engineered on ferritin np to induce a strong immune
response (20). Immunization with HA-np (H1N1 A/New Caledonia/
20/1999) induced a robust antibody response in mice which was
tested against a panel of H1 pseudotyped viruses in a neutralization
assay. Although the antibodies mediated strong neutralization of
related seasonal strains, they only weakly neutralized the un-
matched, highly divergent H1N1 A/Puerto Rico/8/34 influenza
strain [serum half-maximal inhibitory concentrations (IC50)
titer = 210]. In contrast, antibodies elicited by our HA stem
immunogens designed from H1N1 A/Puerto Rico/8/34 showed
strong neutralization of the highly drifted H1 A/New Caledonia/
20/1999 pseudotyped virus (serum IC50 titer ≥ 2622). In addition,
the antibodies also mediated weak neutralization of the highly
pathogenic avian H5 A/Viet Nam/1194/2004 influenza virus.
Examining the immune response of our HA stem immunogens
on an np platform is an interesting future prospect.
The present study demonstrates that the designed HA stem
immunogens elicit nAbs which compete with the bnAb CR6261
for binding to HA. These nAbs probably inhibit the critical step of
virus–host membrane fusion during influenza virus entry. Addi-
tionally, as previously shown in several studies (23, 53, 54), anti-
body-dependent effector functions such as antibody-dependent
cell-mediated cytotoxicity may also contribute to the observed
protection. The detailed mechanism(s) by which our headless
stem immunogens provide protection need further investigation.
HA stem-fragment immunogens induce heterosubtypic immu-
nity. They also confer limited cross-group protection, something
that has been difficult to achieve so far. These immunogens can
also potentially be used as a vaccine strategy to specifically boost
low levels of preexisting, stem-directed, cross-reactive Abs in the
human population. Headless, folded, HA stem-fragment immu-
nogens add to the repertoire of reagents to unambiguously de-
tect influenza HA-stalk specific antibodies in immunological
assays. Most existing influenza vaccine strategies involve expres-
sion in eukaryotic systems and require a cold chain. In contrast,
the immunogens described in this work are bacterially expressed in
soluble form and thermotolerant, allowing for rapid scale-up
during a pandemic outbreak, including in low resource settings.
Materials and Methods
Sequence Analysis. All nonidentical, full-length influenza sequences (4,241
sequences for H1N1 and 182 sequences for H5N1, derived from human hosts)
were obtained from the NCBI Influenza Virus Database. H1N1 sequences
were clustered at 99% homology using Cluster Database at High Identity
with Tolerance to filter out 465 unique, representative H1N1 sequences,
which were used for further analysis (55). These H1N1 sequences were
multiply aligned using ClustalX (56). H1N1 (n = 465) and H5N1 (n = 182)
sequences were also simultaneously aligned using ClustalX. The quality score
for each column in the alignment file is a measure of residue conservation at
that position. The quality scores were binned and mapped onto the crystal
structure of H1N1 A/Puerto Rico/8/34 HA (PDB ID code 1RU7) (34).
Cloning, Expression, and Protein Purification. The gene sequence of our
designed immunogen H1HA10 was synthesized (GenScript) and cloned in the
expression vector pET-28a (+) (Novagen) between NdeI and BamHI re-
striction sites. Gene sequences corresponding to the trimerization motifs IZ
and Foldon were synthesized (Abexome) with flanking KpnI and HindIII
restriction sites. H1HA10-IZ and H1HA10-Foldon derivatives of our pre-
liminary construct were generated by cloning the trimerization motifs at the
C terminus of H1HA10. The stop codon in H1HA10 was mutated to generate
a unique KpnI restriction site using site-directed mutagenesis to facilitate the
cloning of the trimerization motifs. Cloning was confirmed by sequencing
(Macrogen). Gene sequences corresponding to NCH1HA10-Foldon, pH1HA10-
Foldon and H5HA10-Foldon were synthesized (GenScript) and cloned in the
expression vector pET-28a (+) between NdeI and HindIII restriction sites. All
constructs were codon-optimized for expression in E. coli.
The proteins were overexpressed in E. coli BL21(DE3) cells and purified
from the soluble fraction of the cell culture lysate. All proteins in this study
were purified using a similar protocol. Briefly, a single colony of E. coli BL21
(DE3) transformed with the plasmid of interest was inoculated into 50 mL
Tartoff-Hobbs HiVeg media (HiMedia). The primary culture was grown
overnight at 37 °C. Two liters of Tartoff-Hobbs HiVeg media (500 mL ×4)
(HiMedia) was inoculated with 1% of the primary inoculum and grown at
37 °C until an OD600 of ∼0.6–0.8 was reached. Cells were then induced with
1 mM isopropyl-β-thiogalactopyranoside and grown for another 12–16 h at
20 °C. Cells were harvested at 5,000 × g and resuspended in 100 mL PBS (pH
7.4). The cell suspension was lysed by sonication on ice and subsequently
centrifuged at 14,000 × g. The supernatant was incubated with buffer-
equilibrated Ni-NTA resin (GE HealthCare) for 2 h at 4 °C under mild mixing
conditions to facilitate binding. The protein was eluted using an imidazole
gradient (in PBS, pH 7.4) under gravity flow. Fractions containing the protein
of interest were pooled and dialyzed against PBS (pH 7.4) containing 1 mM
EDTA. The dialyzed protein was concentrated in an Amicon (Millipore) stirred
cell apparatus to a final concentration of ∼1 mg/mL. Protein purity was
assessed by SDS/PAGE and its identity confirmed by electrospray ionization MS.
CD. CD spectra for all proteins were recorded on a Jasco J-715C spec-
tropolarimeter flushed with nitrogen gas. The concentration for all proteins
Fig. 4. Immunization with HA stem immunogens protects mice against le-
thal homologous challenge. Mice (n = 10 per group) were primed (day 0)
and boosted (day 28) with 20 μg of the indicated immunogens and chal-
lenged intranasally 21 d after the boost with 1LD90 of mouse-adapted ho-
mologous A/Puerto Rico/8/34 virus. Survival (A) and average weight changes
(only for surviving mice) (B) were monitored for 14 d postchallenge. Naïve
and adjuvant-treated mice were used as controls and showed similar
responses. H1HA10-Foldon conferred complete protection and minimum
weight loss in vivo. H1HA6, a previously characterized stem immunogen
(24) conferred 80% protection. Survival curves were evaluated by Kaplan–
Meier survival analysis with the log-rank significance test (***P ≤ 0.0005,
**P ≤ 0.05, and *P < 0.2). Each data point in B represents the percent
change in mean body weight post-virus challenge. The fractional SE in
measurement was ≤0.82%. The differences in fractional body weight (at
day 14) between the immunized and naïve groups were analyzed by
Student’s t test (***P ≤ 0.0005 and **P ≤ 0.05).
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was ∼5–10 μM. Measurements were done at 25 °C in a 1-mm-path-length
quartz cuvette with a scan rate of 50 nm/min, response time of 4 s, and
a bandwidth of 2 nm. Each spectrum was an average of five scans. Mean
residue ellipticity was calculated as described previously (57). The protein
spectrum was corrected for buffer (PBS, pH 7.4) signals.
For thermal unfolding experiments, the CD signal was monitored as
a function of temperature. Thermal denaturation of H1HA10-Foldon was
monitored at 208 nm, and for H1N1 A/Puerto Rico/8/34 rHA at 215 nm. The
buffer used was PBS (pH 7.4). The data were collected between 15 °C and
90 °C with a 1-°C/min gradient and a data pitch of 0.2 °C. The bandwidth was
2 nm and the response time 4 s. A quartz cuvette of 1-mm-path length was
used. The scan was repeated after cooling the samples back to 15 °C to
measure the reversibility of thermal unfolding.
Fluorescence Spectroscopy. All fluorescence spectra were recorded at 25 °C on
a Jasco FP-6300 spectrofluorimeter. For intrinsic fluorescence measurements,
the protein concentration used was in the range of 1 to 3 μM. The protein
samples were excited at 280 nm, and emission was monitored from 300
to 400 nm. The excitation and emission slit widths were 3 and 5 nm, re-
spectively. Each spectrum was an average of five scans. The data were an-
alyzed after buffer correction. Fluorescence measurements were carried out
under native conditions in PBS (pH 7.4) or under denaturing conditions of
7 M GdnCl in PBS (pH 7.4).
NMR Spectroscopy. One-dimensional 1H NMR spectra were recorded on an
Agilent 600 MHz NMR spectrometer using a triple resonance probe fitted
with a z-axis-only pulsed field gradient accessory. Spectra were recorded at
25 °C. Chemical shifts were referenced to external 2,2-dimethyl-2-silapentane-5-
sulfonic acid. A spectral width of 9,615.4 Hz was sampled. Solvent suppression
was achieved using the excitation sculpting pulse scheme (58). H1HA10-Fol-
don protein samples for NMR were prepared in PBS (pH 7.4) [90% H2O:10%
D2O (vol/vol)]. A total of 2,048 scans were recorded with a 1-s relaxation
delay. Protein sample (H1HA10-Foldon) was prepared in PBS (pH 7.4) [80%
D2O:20% H2O (vol/vol)] for the hydrogen exchange studies. One-dimensional
1H NMR spectra of H1HA10-Foldon were recorded as a function of time over
24 h at every 2-h interval.
Gel-Filtration Chromatography. The oligomeric status of purified proteins was
analyzed under nondenaturing conditions by gel-filtration chromatography
at room temperature on a Superdex-200 analytical gel-filtration column (GE
HealthCare). The column was equilibrated with PBS (pH 7.4) and calibrated
using broad range molecular weight markers (GE HealthCare).
Proteolysis. Proteolytic digestion of the designed immunogens was carried out
using a protease (trypsin)/substratemolar ratio of 1:50. RCAM-RNase Awas used
as a positive control for trypsin activity. Proteolysis was carried out in the
presence of 50 mM Hepes (pH 8.0) and 2 mM CaCl2 on ice. Aliquots were col-
lected at various time points and quenched for trypsin activity with 0.1% formic
acid. Samples collected at different time points were analyzed on 12% SDS/
PAGE followed by staining with Coomassie Brilliant Blue R250 (Sigma).
Binding Affinity Studies Using SPR. Binding affinity of the designed immu-
nogens (H1HA10, H1HA10-IZ, and H1HA10-Foldon) and full-length H1N1
A/Puerto Rico/8/34 rHA (Sino Biological Inc.) to the stem-directed bnAb (CR6261
IgG) or their scFv derivatives (F10-scFv and FI6v3-scFv) was determined by SPR
experiments performedwith a Biacore 3000 optical biosensor (Biacore) at 25 °C.
Recombinant CR6261 IgG was produced in 293T cells as described previously
(24). Plasmids encoding F10-scFv and FI6v3-scFv were synthesized (GenScript)
based on the published sequence (31, 32) and expressed in E. coli. Five hundred
to seven hundred response units (RU) of the ligand (CR6261 IgG, F10-scFv, or
FI6v3-scFv) were immobilized by standard amine coupling to the surface of
a research-grade CM5 chip (GE HealthCare). An ovalbumin-immobilized sensor
channel served as a negative control for each binding interaction. Multiple
concentrations of the analyte were passed over each channel in a running
buffer of PBS (pH 7.4) with 0.05% P20 surfactant. Both binding and dissocia-
tion events were measured at a flow rate of 30 μL/min. The sensor surface was
regenerated after every binding event by repeated washes with 4 M MgCl2.
Each binding curve was analyzed after correcting for nonspecific binding by
subtraction of signal obtained from the negative control flow channel. The
concentration of the monomeric fraction of H1HA10 was used for obtaining
the kinetic paramenters, whereas for H1HA10-IZ, H1HA10-Foldon, and H1N1
A/Puerto Rico/8/34 rHA, concentrations of the trimeric fraction were used. The
kinetic parameters were obtained by globally fitting the data to a simple 1:1
Langmuir interaction model using BIA EVALUATION 3.1 software as described
Fig. 5. Headless HA stem immunogens confer robust subtype-specific and limited cross-group protection in vivo. Mice (n = 10 per group) immunized with the
indicated immunogens were challenged (21 d postsecondary immunization) with an increased lethal challenge dose (2LD90) of mouse-adapted A/Puerto Rico/
8/34 or A/Hong Kong/68 virus. Survival (A and C) and average weight changes (only for surviving mice) (B and D) were monitored for 14 d postchallenge. All of
the HA stem immunogens delayed infection. H1HA10-Foldon conferred robust protection against an increased dose of homologous A/Puerto Rico/8/34 virus
challenge. Significantly, NCH1HA10-Foldon protected mice against a heterologous A/Puerto Rico/8/34 virus challenge. H5HA10-Foldon, designed from an H5
subtype also provided partial protection against heterologous A/Puerto Rico/8/34 virus challenge and protected mice recovered completely. H1HA6 (designed
from H1N1 A/Puerto Rico/8/34), a previously characterized stem immunogen (24) conferred 80% protection. pH1HA10-Foldon also conferred limited pro-
tection against a lethal H3N2 A/Hong Kong/68 virus challenge. The surviving mice showed significant weight recovery. Survival curves were evaluated by
Kaplan–Meier survival analysis with the log-rank significance test (***P ≤ 0.0005, **P ≤ 0.05, and *P < 0.2). Each data point in B and D represents the percent
change in mean body weight post-virus challenge. The fractional SE in measurement was ≤0.82%. The differences in fractional body weight (at day 14)
between the immunized and naïve groups were analyzed by Student’s t test (***P ≤ 0.0005 and **P ≤ 0.05). In B the fractional body weight of the naïve
group at day 11 was used for analysis as all of the mice in this group had succumbed to virus challenge by the end of the study period.
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previously (38). Trace 1 (Fig. S7B) was omitted from global fitting while
obtaining the kinetic parameters for H1HA10-IZ because it could not be fitted
to a 1:1 interaction model.
Thermal tolerance of H1HA10-Foldon was assessed by its ability to bind
CR6261 after heat stress. The protein sample was incubated at 40 °C, 60 °C,
and 80 °C for 1 h in a PCR cycler (BioRad) with a heated lid to prevent
evaporation. The samples were cooled to 25 °C and binding affinity to CR6261
was determined by SPR experiments as described above.
Pull-Down Assay. The ability of H1HA10-Foldon to form a stable complex with
the bnAb CR6261 IgG was further confirmed in a pull-down assay. CR6261 and
H1HA10-Foldon were mixed together at different molar ratios and incubated
for 2 h at 4 °C. Buffer (PBS, pH 7.4)-equilibrated Protein G (GE HealthCare)
beads were added to the complex and incubated for 1 h to specifically pull
down CR6261 IgG. The beads were spun down at 3,000 × g for 15 min at 4 °C.
The unbound supernatant was separated and the beads were washed with PBS
(pH 7.4). The antibody bound to the beads was eluted with 100 mMglycine·HCl
(pH 3.0). The eluted fractions were neutralized with 1 M Tris·HCl (pH 9.0). The
unbound and eluted fractions were subsequently analyzed by SDS/PAGE.
Immunization and Challenge Studies. Female BALB/c mice (4–5 wk old)
(Taconic Farms, Inc.) were maintained at the animal facilities of Merck Re-
search Laboratories. The study design was approved by the Merck Research
Laboratories Institutional Animal Care and Use Committee. Mice (10 mice per
group) were immunized intramuscularly with 20 μg test immunogen along
with 100 μg CpG7909 adjuvant (TriLink BioTechnologies) at days 0 (prime) and
28 (boost). Naïve (buffer-only) mice and adjuvant-treated mice were used as
controls. Serum samples obtained from tail vein venipuncture were collected
in Microtainer serum separator tubes (BD Biosciences) 21 d after the prime-
and 14 d postboost from all of the mice. Twenty-one days after the secondary
immunization, mice were anesthetized with ketamine/xylazine and challenged
intranasally with 1LD90 of mouse-adapted H1N1 A/Puerto Rico/8/34 virus in
20 μL PBS. To test for protection against a higher dose of the virus, one group
of mice primed and boosted with H1HA10-Foldon was challenged with 2LD90
of homologous A/Puerto Rico/8/34 virus. The ability of NCH1HA10-Foldon,
pH1HA10-Foldon and H5HA10-Foldon to confer cross-protection was evalu-
ated against a stringent 2LD90 heterologous H1N1 A/Puerto Rico/8/34 virus
challenge. Another group of mice (n = 10) immunized with pH1HA10-Foldon
were challenged with 2LD90 heterologous, mice-adapted H3N2 A/Hong
Kong/68 virus. Survival and weight change of the challenged mice were
monitored daily for 14 d postchallenge. At each time point, all surviving
mice of a group were weighed together and the mean weight calculated.
Errors in the mean weight were estimated from three repeated measure-
ments of the mean weight of the same number of healthy mice.
Determination of Serum Antibody Titers. Antibody titers against test immu-
nogens were determined by ELISA. Briefly, test immunogens were coated on
96-well Nunc plates (Thermo Fisher Scientific) at 4 μg/mL in 50 μL PBS at 4 °C
overnight. Plates were then washed with PBS containing 0.05%Tween-20
(PBST) and blocked with 3% skim milk in PBST for 1 h. One hundred microliters
of the antisera raised against the test immunogens was diluted in a fourfold
series in milk–PBST and added to each well. Plates were incubated for 2 h at
room temperature followed by washes with PBST. Fifty microliters of HRP-con-
jugated goat anti-mouse IgG (H+L) secondary antibody (Invitrogen) in milk–PBST
was added to each well at a predetermined dilution (1:5,000) and incubated at
room temperature for 1 h. Plates were washed with PBST followed by de-
velopment with 100 μL per well of the substrate 3,3′,5,5′-tetramethylbenzidine
(TMB) solution (Virolabs) and stopped after 3–5 min of development with 100 μL
per well of the stop solution for TMB (Virolabs). OD at 450 nm was measured
and the antibody titer was defined as the reciprocal of the highest dilution that
gave an OD value above the mean plus 2 SDs of control wells.
Binding of Antisera to Recombinant HAs. Binding of antisera raised against the
test immunogens to several rHA proteins was determined by ELISA. Briefly,
mammalian-expressed rHA proteins (H1N1 A/Puerto Rico/8/34, H1N1 A/
California/04/2009, H1N1 A/Brisbane/59/2007, H5N1 A/Viet Nam/1203/2004,
H3N2 A/Aichi/2/68, and H3N2 A/Brisbane/10/07; Sino Biological Inc.) were
coated on 96-well Nunc plates (Thermo Fisher Scientific) at 2.5 μg/mL in 50 μL
PBS at 4 °C overnight. Ovalbumin (125 ng per well)-coated wells were used
as a negative control. Plates were washed with PBST and blocked with 1% BSA
in PBST (PBSB). Antisera were then added to each well at a starting dilution of
1:100 followed by a fourfold dilution series and incubated for 2 h. Plates were
washed with PBST. Alkaline phosphatase (ALP)-conjugated goat anti-mouse
secondary antibody (Sigma) in PBSB was added to each well at a pre-
determined dilution (1:10,000) and incubated at room temperature for 2 h.
Plates were washed and developed using the chromogenic substrate p-nitro-
phenyl phosphate (Sigma). Plates were read at 405 nm (SPECTRAmax Plus 384;
Molecular Devices). Antibody titer was defined as the reciprocal of the highest
dilution that gave an OD value above the mean plus 2 SDs of control wells.
Neutralization Assay. HA-pseudotyped lentiviral particles were produced as
described previously (48, 59). Briefly, HIV gag-pol plasmid p8.91, firefly lu-
ciferase expressing plasmid pCSFLW, HA (H1N1 A/Puerto Rico/8/1934, H1N1
A/New Caledonia/20/1999, H1N1 A/Brisbane/59/2007, H1N1 A/South Carolina/1/
1918, H5N1 A/Viet Nam/1194/2004, and H3N2 A/Udorn/307/1972) expressing
plasmid, and pCAGGS-HAT or pCAGGS-TMPRSS2 (60) (for H1 and H3 pseudo-
types) expressing plasmid were cotransfected into human embryonic kidney
(HEK 293T/17) cells using Fugene-6 transfection reagent (Promega). Twenty-
four hours postincubation, recombinant neuraminidase (Sigma) was added
to facilitate the release of the pseudotype virus. Forty-eight hours post-
transfection, supernatant containing the released pseudotype virus was
harvested, filtered through 0.45-μm filter, and stored at −80 °C.
Pseudotype virus [1 × 106 relative luminescence units per well] was in-
cubated with serial dilutions of immunized mice sera in 96-well flat-
bottomed white plates (Nunc) in a final volume of 100 μL and incubated at
37 °C. After 1 h, 1 × 104 HEK293T/17 cells were added to each well and the
plates were incubated for another 48 h at 37 °C. Luminescence was evalu-
ated using the Bright-Glo assay system (Promega). IC50 of neutralization
were calculated with Prism Version 6.0e (GraphPad Software).
Competition ELISA. Competition ELISA between the antisera raised against
the test immunogens and the bnAb CR6261 IgG was carried out as described
elsewhere (50). Briefly, 96-well half area plates (Corning Incorporated) were
coated with 3 μg pandemic H1N1 A/California/04/2009 rHA (Sino Biological
Inc.) in 50 μL PBS and kept overnight at 4 °C. Ovalbumin (3 μg)-coated wells
were used as negative control for antisera binding. Plates were washed with
PBST and blocked for 1 h with PBSB. Twenty-five microliters of antisera were
added to each well starting at a 1:100 dilution followed by a threefold serial
dilution in PBSB. As a control for nonspecific competition, a previously
characterized head-specific neutralizing mAb IgG MA2077 was used (50).
Twenty-five microliters of mAb MA2077 was added to each well starting at
a concentration of 2 mg/mL followed by threefold serial dilutions. After 2 h
of incubation, the plates were washed and blocked with PBSB for 15 min.
CR6261 was then added to each well at a fixed concentration (300 ng/mL) as
determined from the titration curve of CR6261 with pandemic H1N1 rHA.
After 2 h of incubation with CR6261, the plates were washed with PBST. The
wells were then probed with 25 μL of ALP-conjugated goat anti-human
antibody (Sigma) at a predetermined dilution (1:10,000) to detect the bound
CR6261. The plates were washed and developed using the chromogenic sub-
strate p-nitrophenyl phosphate (Sigma). The optical density was measured at
405 nm (SPECTRAmax Plus 384L; Molecular Devices). The percent competition
was calculated as follows: % competition = [(A − P)/A] × 100, where A is the
signal of CR6261 binding to rHA in the absence of antiserum and P is the
binding signal of CR6261 to rHA in the presence of antiserum (24).
Statistical Analysis. Differences in antibody/neutralization titers and mean
fractional body weights of surviving mice between different groups were
analyzed by analysis of variance and Student’s t test. The fractional body
weight of mice is calculated relative to their starting body weight. Differ-
ences in survival were calculated by Kaplan–Meier survival analysis with the
log-rank significance test.
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